WeVote
Log In

Bill

SB

Bill

HR 5646

Restoring Safeguards for Dangerous Abortion Drugs Act

119th Congress Introduced by Sheri Biggs and 7 co-sponsors

HR 5646 aims to tighten regulations on abortion drugs, impacting patient access, healthcare provider protocols, and pharmaceutical oversight to enhance safety and efficacy.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 5646

Summary of HR 5646: Restoring Safeguards for Dangerous Abortion Drugs Act

Bill Overview

  • Bill Number: HR 5646
  • Title: Restoring Safeguards for Dangerous Abortion Drugs Act
  • Status: Introduced in House
  • Introduced On: September 30, 2025
  • Classification: Bill

Purpose and Intent

The Restoring Safeguards for Dangerous Abortion Drugs Act aims to enhance regulatory oversight and safety measures concerning the distribution and use of certain abortion drugs. The bill seeks to address concerns regarding the safety and efficacy of these medications, ensuring that they are used in a manner that prioritizes patient health and safety.

Key Provisions

While the specific text of the bill is not provided, the following provisions are typically expected in legislation of this nature:

  1. Increased Regulatory Oversight:

    • The bill may propose stricter guidelines for the approval and distribution of abortion drugs, potentially requiring additional clinical trials or safety studies.

  2. Labeling and Information Requirements:

    • Enhanced labeling requirements to ensure that patients receive comprehensive information about the risks and side effects associated with abortion drugs.

  3. Prescription and Dispensing Protocols:

    • The introduction of new protocols for how these drugs are prescribed and dispensed, possibly requiring them to be administered in a clinical setting rather than through telehealth or mail-order services.

  4. Monitoring and Reporting:

    • Establishing a system for monitoring adverse effects and complications associated with abortion drugs, along with mandatory reporting requirements for healthcare providers.

Affected Parties

The following groups may be impacted by the provisions of HR 5646:

  • Patients: Individuals seeking abortion services may face new barriers or requirements in accessing abortion drugs.
  • Healthcare Providers: Medical professionals prescribing or dispensing abortion drugs will need to comply with new regulations and protocols.
  • Pharmaceutical Companies: Manufacturers of abortion drugs may face increased scrutiny and regulatory requirements, potentially affecting their market practices.

Procedural Aspects

  • Committee Referrals: On the day of its introduction, HR 5646 was referred to the Committee on Energy and Commerce and the Committee on the Judiciary. The Speaker will determine the period for consideration by these committees.
  • Next Steps: The bill will undergo review and discussion within the committees before potentially moving forward for a vote in the House.

Conclusion

HR 5646 represents a significant legislative effort to impose stricter regulations on abortion drugs, reflecting ongoing debates surrounding reproductive health. As the bill progresses through the legislative process, further details will emerge regarding its specific provisions and potential implications for healthcare practices and patient access.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.